Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Cancer cells are able to escape surveillance from the immune system by co-opting physiologic mechanisms such as the programmed cell death-1 (PD-1) receptor pathway. Agents able to block the interaction between the PD-1 receptor and its ligands have the potential to release T cells from tumor-induced suppression and eradicate malignant cells. Nivolumab-a PD-1 inhibitor-is approved for the treatment of patients with metastatic melanoma and lung cancer. This agent has been tested in patients with advanced Hodgkin lymphoma (HL) and showed impressive results in a phase I trial. Here we review the profile of Nivolumab including its pharmacological properties, clinical efficacy and safety in patients with advanced classical HL.

Original languageEnglish (US)
Pages (from-to)5-12
Number of pages8
JournalExpert Review of Anticancer Therapy
Volume16
Issue number1
DOIs
StatePublished - Jan 2 2016

Keywords

  • checkpoint inhibitors
  • Hodgkin lymphoma
  • immunerelated adverse events
  • Immunotherapy
  • nivolumab
  • PD-1
  • PD-L1

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Fingerprint Dive into the research topics of 'Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab'. Together they form a unique fingerprint.

  • Cite this